Global Cancer Immunotherapy Market and Clinical Trials Outlook 2022

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

“Global Cancer Immunotherapy Market and Clinical Trials Outlook 2022” report gives comprehensive insight on clinical and non-clinical developments in the field of cancer immunotherapy. According to report, cancer immunotherapy has emerged as the new growth frontier for the pharmaceutical companies involved in the clinical research and development of cancer drugs and therapeutics. Currently there are more than 2000 cancer immunotherapies based drugs/therapies are in clinical pipeline. Majority of these are in preclinical, Phase-I and Phase-II trials. There are 14 cancer vaccine, 44 Cancer monoclonal antibodies, 3 cancer cell therapies and 61 cancer Immunomodulators are commercially available in the market.

Pharmaceutical companies are actively engaged in research and development of cancer immunotherapies because of large unmet medical necessities. Investigators are trying to come forth with innovative cancer immunotherapeutic products having high safety and efficacy profiles which are not offered by conventional therapeutics. Higher investments in research and development segment could significantly increase the drug discovery rates which will alleviate the medical condition of cancer patients. Simultaneously, technological advancements are being made due to which development of worthy candidates with high commercialization and pharmacological potential is expected to increase in coming years.

Investigators are trying to decipher underlying principle of cancer progression and proliferation. Different cancer indications have different requirements for developing effective therapeutics due to which identification of these factors have become important. This knowledge would be used for developing innovative cancer immunotherapies for various malignancies.

Cancer immunotherapeutics based on these discoveries would pave path for market introduction of highly effective therapeutics. Some progress has been made which could be noticed by observing plethora of cancer immunotherapeutics available for different cancer indications. Their clinical pipeline is also developing rapidly and various products are at different stages of clinical trials. They are expected to offer severe competition to presently available cancer therapeutics with modest pharmacological efficacy.

Cancer immunotherapies have been used for limited number of malignancies as compared to other drug categories. Mostly hematological malignancies like follicular lymphoma, chronic lymphocytic leukemia and diffuse large B cell non-Hodgkin’s lymphoma have remained the focal point. Other cancer indications like melanoma, NSCLC, prostate cancer and RCC have also got cancer immunotherapeutics.

Most like, cancer therapeutics in clinical trials would be able to present positive data that will allow them to easily enter in global market. Cancer incidences are escalating rapidly and cancer immuno therapeutics seems to play an important role in offering better medical care to patients. Some of them have received FDA’s accelerated approval and breakthrough therapy designation due to their superior pharmacological benefits. It is expected that similar progress would be shown by cancer immunotherapeutics under development for different malignancies.

“Global Cancer Immunotherapy Market and Clinical Trials Outlook 2022” report highlights:

Categorization of Cancer Immunotherapy
Market Aspects of Cancer Immunotherapy
Clinical Trials and Development Insight
Global Cancer Immunotherapy Pipeline Overview
Marketed Cancer Immunotherapy by Class
Global Cancer Immunotherapy Market Future Prospects

Competitive Analysis

1. Immunotherapy: Mending Cancer Regimens

1.1 Preface to Cancer Immunotherapy

1.2 Evolution of Cancer Immunotherapy

2. Categorization of Cancer Immunotherapy

2.1 Specific Cancer Immunotherapy

2.1.1 Cancer Vaccines

2.1.2 Monoclonal Antibodies

2.2 Non-Specific Cancer Immunotherapy

2.2.1 Adoptive Cell Transfer Immunotherapy

2.2.2 Immune Checkpoint Inhibitors

3. Fundamentals of Cancer Vaccines

3.1 Prologue of Cancer Vaccines

3.2 Cancer Vaccines in Immunotherapy

3.3 Commercial Aspects of Cancer Vaccines

4. New Era of Monoclonal Antibodies

4.1 Rudiments of Monoclonal Antibodies

4.2 Advents of Monoclonal Antibodies

4.3 Commercial Aspects of Monoclonal Antibodies

5. Trails of T-Cell Therapies

5.1 Adoptive Cell Transfer Technology

5.2 Strategies of Adoptive Cell Transfer

5.3 Commercial Aspects of Adoptive Cell Therapy

6. Aspects of Immune Checkpoint Inhibitors

6.1 Prelude to Immune Checkpoint Inhibitors

6.2 Implications of Immunecheck Point Inhibitors

6.3 Commercial Aspects of Immune Checkpoint Inhibitors

7. Immunomodulators in Cancer Immunotherapy

7.1 Perspective of Immunomodulators

7.2 Clinical Aspects of Immunomodulators

7.3 Commercial Aspects of Immunomodulators

8. Oncolytic Viral Immunotherapy

8.1 Concept to Oncolytic Viruses

8.2 Potential Approaches of Oncolytic Viruses

8.3 Commercial Aspects of Oncolytic Viruses

9. Cytokines in Cancer Immunotherapy

9.1 Fundamentals of Cytokines

9.2 Classification of Cytokines

9.3 Commercial Aspects of Cytokines

10. Interferons in Immunotherapy

10.1 Potentials of Interferons

10.2 Classification of Interferons

10.3 Clinical Applications of Interferons

11. Interleukins in Immunotherapy

11.1 Potentials of Interleukins

11.2 Clinical Applications of Interleukins

12. GM-CSF in Immunotherapy

12.1 Potentials of GM-CSF

12.2 Clinical Applications of GM-CSF

13. Global Economic Evaluations

13.1 Economic Aspects of Cancer Immunotherapy

13.2 Cancer Immunotherapy Cost by Product

14. Market Aspects of Cancer Immunotherapy

14.1 Current Market Trends

14.2 Cancer Immunotherapy Pipeline Overview

15. Global Cancer Immunotherapy Market Dynamics

15.1 Favorable Market Parameters

15.2 Commercialization Challenges

16. Marketed Cancer Cell Therapies Drugs

16.1 Sipuleucel-T (Provengeandreg;)

16.2 T-Lymphocyte Cell Therapy(Immuncell-LCandreg;)

17. Marketed Cancer Cytokines Drugs

17.1 Aldesleukin (Proleukinandreg;)

17.2 Denileukin Diftitox (ONTAKandreg;)

17.3 Interferon Alpha (Multiferonandreg;)

17.4 Interferon Alpha-2a (Roferon-Aandreg;)

17.5 Interferon Alpha-2a (Veldonaandreg;)

17.6 Interferon Alpha-2a Biosimilar(Inferonandtrade;/Inmutagandtrade;)

17.7 Interferon Alpha-2b(Intronandreg; A)

17.8 Interferon Alpha-2b Biosimilar(Bioferonandtrade;)

17.9 Interferon Alpha-2b Biosimilar (Intalfaandreg;)

17.10 Interferon Alpha-2b Biosimilar

17.11 Interferon-Alpha-n3 (Alferon Nandreg;)

17.12 Interferon-Beta-1b (Feronandreg;)

17.13 Interferon-Gamma (Ogammaandreg;)

17.14 Interleukin-2 Biosimilar (Ilcass)

17.15 Teceleukin (Imunaceandtrade;)

18. Marketed Cancer Vaccines

18.1 Bladder Cancer Vaccine (PACISandreg;)

18.2 Bladder Cancer Vaccine

18.3 BV NSCLC 001

18.4 Dendritic Cell Vaccine (CreaVax-HCCandreg;, CreaVax-PCandreg; and CreaVax-RCCandreg;)

18.5 Human Papillomavirus Vaccine Quadrivalent (Gardasilandreg;/Silgardandreg;)

18.6 Human Papillomavirus Vaccine Recombinant Bivalent (Cervarixandreg;)

18.7 Melanoma Vaccine (MVaxandreg;)

18.8 Melanoma Vaccine (Melacineandreg;)

18.9 Racotumomab (Vaxiraandreg;)

18.10 Sipuleucel-T (Provengeandreg;)

18.11 Tertomotide (LucaVax)

18.12 Vitespen (Oncophageandreg;)

19. Marketed Cancer Monoclonal Antibodies

19.1 Bevacizumab

19.2 Trastuzumab Emtansine

19.3 Trastuzumab Subcutaneous

19.4 Brentuximab Vedotin

19.5 Catumaxomab

19.6 Ipilimumab

19.7 Nivolumab

19.8 Pembrolizumab

19.9 Pertuzumab

19.10 Rituximab

19.11 Trastuzumab

20. Global Cancer Immunotherapy Market Future Prospects

21. Competitive Landscape

21.1 Abbvie

21.2 Advaxis

21.3 Altor BioScience

21.4 Amgen

21.5 Biogen Idec

21.6 Biogenomics

21.7 Celldex Therapeutics

21.8 Dendreon Corporation

21.9 Eli Lilly

21.10 Expression Genetics

21.11 Galena Biopharma

21.12 Genmab

21.13 Gilead Sciences

21.14 GlaxoSmithKline

21.15 ImmunoCellular Therapeutics

21.16 ImmunoGen

21.17 Inovio Pharmaceuticals

21.18 IRX Therapeutics

21.19 Merck

21.20 NeoStem Oncology

21.21 NewLink Genetics

21.22 Northwest Biotherapeutics

21.23 Novartis

21.24 Peregrine Pharmaceuticals

21.25 Pfizer

21.26 Philogen

21.27 Regulon

21.28 Roche

21.29 Seattle Genetics

21.30 ZymoGenetics

Figure 1-1: Evolutionary Trails of Cancer Immunotherapy

Figure 1-2: Layout of Necessity of Cancer Immunotherapies for Cancer Treatment

Figure 1-3: Potential Benefits of Cancer Immunotherapies

Figure 2-1: Classification of Cancer Immunotherapies

Figure 2-2: Categorization of Specific Immunotherapy

Figure 2-3: Non-Specific Cancer Immunotherapies

Figure 3-1: Categorization and Function of Cancer Vaccines

Figure 3-2: Mechanism of the Cancer Vaccine towards Tumor Eradication

Figure 3-3: Global Cancer Vaccines Market (US$ Billion), 2016-2022

Figure 4-1: Process of Manufacturing of Monoclonal Antibody

Figure 4-2: Principles of Monoclonal Antibodies

Figure 4-3: Evolution of Monoclonal Antibody over Generations

Figure 4-4: Classification of Monoclonal Antibodies

Figure 4-5: Representation of Mechanism of Alemtuzumab

Figure 4-6: Representation of Mechanism of Ibritumomab Tiuxetan

Figure 4-7: Representation of Mechanism of Blinatumomab

Figure 4-8: Global Market for Cancer Monoclonal Antibodies (US$ Billion), 2016-2022

Figure 5-1: Benefit of Adoptive Cell Transfer Immunotherapy

Figure 5-2: Systematic Representation of Adoptive T-Cell Therapies

Figure 5-3: Three Adoptive Cell Transfer Strategies for Cancer Immunotherapy

Figure 5-4: Tumor-Infiltrating Lymphocytes in Adoptive Cell Transfer

Figure 5-5: Mechanism of CAR Modified T-Cells

Figure 5-6: Genetically Engineered TCR for Cancer Immunotherapy

Figure 5-7: Global Predictive Market of CAR T-Cell Therapeutics (US$ Million), 2016-2022

Figure 6-1: Benefits of Immune Checkpoint Inhibitors

Figure 6-2: Implication of Adaptive Immune Resistance Mechanism

Figure 6-3: Mechanism of Ipilimumab

Figure 6-4: Layout of Mechanism of Nivolumab

Figure 6-5: Mechanism of Pembrolizumab

Figure 6-6: Global - Immune Check Point Inhibitors Market (US$ Billion), 2016-2022

Figure 7-1: Functions of Immunomodulators

Figure 7-2: Benefits of Immunomodulators

Figure 7-3: Layout of the Challenges of Immunomodulators

Figure 7-4: Properties of Thalidomide

Figure 7-5: Mechanism of Lenalidomide In Vivo

Figure 7-6: Mechanism of Lenalidomide in Vitro

Figure 7-7: Mechanism of Pomalidomide

Figure 7-8: The Global Market for Immunomodulators for All Indications (US$ Billion), 2016-2022

Figure 8-1: Demonstration of Categorization of Oncolytic Viruses

Figure 8-2: Potential Advantages of Oncolytic Viruses over Conventional Therapies

Figure 8-3: The Predicted Market Share of Oncolytic Viral Therapies (US$ Million), 2016-2022

Figure 9-1: Layout of Functions Performed by Cytokine

Figure 9-2: Benefits of Cytokines in Cancer Immunotherapy

Figure 9-3: Classification of Cytokine Receptor Family

Figure 9-4: Percentage Share of the Cancer Immunotherapies by the Technology

Figure 10-1: Layout of Functions of Interferon

Figure 10-2: Classification of Interferons on the Basis of Types of Genes

Figure 10-3: General Mechanism of Interferons

Figure 10-4: Mechanism of Interferon Alfa-n3

Figure 10-5: Aspects of Peginterferon Alfa-2a

Figure 10-6: Applications of Interferon Beta 1a

Figure 10-7: Potentials of Interferon Alfa-2b

Figure 11-1: Functions of Interleukin

Figure 11-2: Potentials of Interleukins in Cancer Immunotherapy

Figure 11-3: Clinical Potentials of Proleukin

Figure 11-4: Clinical Potentials of Denileukin Diftitox

Figure 12-1: Potential Applications of GM-CSF

Figure 12-2: Mechanism of Sargramostim

Figure 13-1: Expected Cancer Treatment Cost (US$ Billion), 2016-2022

Figure 13-2: Comparative Analysis of Available Cancer Treatments

Figure 13-3: Major Approved Immunotherapeutic Drugs

Figure 13-4: Annual per Patient Drug Expenditure of Immunotherapy

Figure 14-1: Global Cancer Immunotherapeutic Market (US$ Billion), 2016-2022

Figure 14-2: Global - Cancer Vaccine Clinical Pipeline by Phase (%), 2017 - 2022

Figure 14-3: Global - Cancer Vaccine Clinical Pipeline by Phase (Number), 2017 -2022

Figure 14-4: Global - Cancer Vaccine Suspended/Discontinued in Clinical Pipeline by Phase (%), 2017 -2022

Figure 14-5: Global - Cancer Vaccine Suspended/Discontinued in Clinical Pipeline by Phase (Number), 2017 -2022

Figure 14-6: Global - Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2017 -2022

Figure 14-7: Global - Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2017 -2022

Figure 14-8: Global - Cancer Cell Therapies Clinical Pipeline by Phase (%), 2017 -2022

Figure 14-9: Global - Cancer Cell Therapies Clinical Pipeline by Phase (Number), 2017 -2022

Figure 14-10: Global - Cancer Cell Therapies Suspended/Discontinued in Clinical Pipeline by Phase (%), 2017 -2022

Figure 14-11: Global - Cancer Cell Therapies Suspended/Discontinued in Clinical Pipeline by Phase (Number), 2017 - 2022

Figure 14-12: Global - Cancer Immunomodulators Clinical Pipeline by Phase (%), 2017 - 2022

Figure 14-13: Global - Cancer Immunomodulators Clinical Pipeline By Phase (Number), 2017 - 2022

Figure 15-1: Favorable Cancer Immunotherapy Market Parameters

Figure 15-2: Cancer Immunotherapy Commercialization Challenges

Figure 21-1: Advaxis Clinical Pipeline

Figure 21-2: Celldex Therapeutics Clinical Pipeline

Figure 21-3: Expression Genetics Clinical Pipeline

Figure 21-4: Galena Biopharma Clinical Pipeline

Figure 21-5: ImmunoCellular Therapeutics Clinical Pipeline

Figure 21-6: ImmunoGen Clinical Pipeline

Figure 21-7: Inovio Pharmaceuticals Clinical Pipeline

Figure 21-8: NewLink Genetics Corporation Clinical Pipeline

Figure 21-9: Northwest Biotherapeutics Clinical Pipeline

Figure 21-10: Peregrine Pharmaceuticals Clinical Pipeline

Figure 21-11: Philogen Clinical Pipeline

Figure 21-12: Seattle Genetics Clinical Pipeline

Table 4-1: Different Monoclonal Antibodies Used in Cancer Immunotherapy

Table 6-1: Illustration of Some Important Checkpoint Inhibitors

Table 9-1: Few Important Immunocytokines under Clinical Development

Table 9-2: Some Pharmacologically Important Cytokines Used in Cancer Immunotherapies

Table 14-1: Few Commercially Important PD-1 Drugs

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Payment Request

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Accept Terms & Conditions And Privacy Policy

Global Cancer Immunotherapy Market and Clinical Trials Outlook 2022

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

“Global Cancer Immunotherapy Market and Clinical Trials Outlook 2022” report highlights:

Categorization of Cancer Immunotherapy

Market Aspects of Cancer Immunotherapy

Clinical Trials and Development Insight

Global Cancer Immunotherapy Pipeline Overview

Marketed Cancer Immunotherapy by Class

Global Cancer Immunotherapy Market Future Prospects

Competitive Analysis

1. Immunotherapy: Mending Cancer Regimens

1.1 Preface to Cancer Immunotherapy

1.2 Evolution of Cancer Immunotherapy

2. Categorization of Cancer Immunotherapy

2.1 Specific Cancer Immunotherapy

2.1.1 Cancer Vaccines

2.1.2 Monoclonal Antibodies

2.2 Non-Specific Cancer Immunotherapy

2.2.1 Adoptive Cell Transfer Immunotherapy

2.2.2 Immune Checkpoint Inhibitors

3. Fundamentals of Cancer Vaccines

3.1 Prologue of Cancer Vaccines

3.2 Cancer Vaccines in Immunotherapy

3.3 Commercial Aspects of Cancer Vaccines

4. New Era of Monoclonal Antibodies

4.1 Rudiments of Monoclonal Antibodies

4.2 Advents of Monoclonal Antibodies

4.3 Commercial Aspects of Monoclonal Antibodies

5. Trails of T-Cell Therapies

5.1 Adoptive Cell Transfer Technology

5.2 Strategies of Adoptive Cell Transfer

5.3 Commercial Aspects of Adoptive Cell Therapy

6. Aspects of Immune Checkpoint Inhibitors

6.1 Prelude to Immune Checkpoint Inhibitors

6.2 Implications of Immunecheck Point Inhibitors

6.3 Commercial Aspects of Immune Checkpoint Inhibitors

7. Immunomodulators in Cancer Immunotherapy

7.1 Perspective of Immunomodulators

7.2 Clinical Aspects of Immunomodulators

7.3 Commercial Aspects of Immunomodulators

8. Oncolytic Viral Immunotherapy

8.1 Concept to Oncolytic Viruses

8.2 Potential Approaches of Oncolytic Viruses

8.3 Commercial Aspects of Oncolytic Viruses

9. Cytokines in Cancer Immunotherapy

9.1 Fundamentals of Cytokines

9.2 Classification of Cytokines

9.3 Commercial Aspects of Cytokines

10. Interferons in Immunotherapy

10.1 Potentials of Interferons

10.2 Classification of Interferons

10.3 Clinical Applications of Interferons

11. Interleukins in Immunotherapy

11.1 Potentials of Interleukins

11.2 Clinical Applications of Interleukins

12. GM-CSF in Immunotherapy

12.1 Potentials of GM-CSF

12.2 Clinical Applications of GM-CSF

13. Global Economic Evaluations

13.1 Economic Aspects of Cancer Immunotherapy

13.2 Cancer Immunotherapy Cost by Product

14. Market Aspects of Cancer Immunotherapy

14.1 Current Market Trends

14.2 Cancer Immunotherapy Pipeline Overview

15. Global Cancer Immunotherapy Market Dynamics

15.1 Favorable Market Parameters

15.2 Commercialization Challenges

16. Marketed Cancer Cell Therapies Drugs

16.1 Sipuleucel-T (Provengeandreg;)

16.2 T-Lymphocyte Cell Therapy(Immuncell-LCandreg;)

17. Marketed Cancer Cytokines Drugs

17.1 Aldesleukin (Proleukinandreg;)

17.2 Denileukin Diftitox (ONTAKandreg;)

17.3 Interferon Alpha (Multiferonandreg;)

17.4 Interferon Alpha-2a (Roferon-Aandreg;)

17.5 Interferon Alpha-2a (Veldonaandreg;)

17.6 Interferon Alpha-2a Biosimilar(Inferonandtrade;/Inmutagandtrade;)

17.7 Interferon Alpha-2b(Intronandreg; A)

17.8 Interferon Alpha-2b Biosimilar(Bioferonandtrade;)

17.9 Interferon Alpha-2b Biosimilar (Intalfaandreg;)